ANDA 214267, held by Pharmobedient. Lidocaine Hydrochloride.
As of Nov 16, 2026, ANDA 214267 (Lidocaine Hydrochloride), held by Pharmobedient, was first approved by FDA on Sep 19, 2022, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 19, 2022 | Original application | Approved | None posted |
| Lidocaine Hydrochloride1% · injectable;injection | Lidocaine Hydrochloride | Rx |
| Lidocaine Hydrochloride2% · injectable;injection | Lidocaine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters